

**Editor**

Leo van de Putte (The Netherlands)

**Associate Editors**

Thomas Bardin (France)  
Johannes Bijlsma (The Netherlands)  
Gerd Burmester (Germany)

Bevrah Hahn (USA)  
Frank Wollheim (Sweden)  
Anthony Woolf (UK)

**Methodological Adviser**

Jaap Fransen (The Netherlands)

**Editorial Board**

M Aringer (Austria)  
P Bacon (UK)  
F Berenbaum (France)  
M Boers (The Netherlands)  
D Boumpas (Greece)  
B Bresnihan (Ireland)  
H Capell (UK)  
M Cutolo (Italy)  
G Firestein (USA)  
P Goupille (France)  
E Gravalles (USA)  
W Gross (Germany)  
F Guillemin (France)  
G Herrero-Beaumont (Spain)  
F Houssiau (Belgium)  
T Huizinga (The Netherlands)  
C Jorgensen (France)  
G Kollias (Greece)  
T Kvien (Norway)  
M Leirisalo-Repo (Finland)  
F Luijten (Belgium)  
H-M Lorenz (Germany)  
W Maslinski (Poland)  
M Matsuura Cerinic (Italy)

K Nishioka (Japan)  
M Nurmohamed (The Netherlands)  
S Özen (Turkey)  
T Pap (Germany)  
E Pascual Gómez (Spain)  
L Punzi (Italy)  
L Rönblom (Sweden)  
B Rozman (Slovenia)  
G Schett (Austria)  
J Da Silva (Portugal)  
H Schulze-Koops (Germany)  
A So (Switzerland)  
T Sokka (USA)  
D Symmons (UK)  
P-P Tak (The Netherlands)  
A Tyndall (Switzerland)  
A Tzioufas (Greece)  
J Vencovsky (Czech Republic)  
M Ward (USA)  
M Weisman (USA)  
H Yazici (Turkey)  
Editor, *BMJ*

**Advisory Committee**

W vd Berg (The Netherlands)  
S Bombardieri (Italy)  
F Breedveld (The Netherlands)  
L Crofford (USA)  
J-M Dayer (Switzerland)  
M Doherty (UK)  
M Dougados (France)  
J Edmonds (Australia)  
P Emery (UK)  
D Furst (USA)  
S Gay (Switzerland)  
J Kalden (Germany)  
E Keystone (Canada)  
L Klareskog (Sweden)

P Lipsky (USA)  
S Lohmander (Finland)  
R Maini (UK)  
E M Mola (Spain)  
H Moutsopoulos (Greece)  
J O'Dell (USA)  
K Pavelka (Czech Republic)  
J Rovinsky (Slovakia)  
Y Shoenfeld (Israel)  
J Smolen (Austria)  
W van Venrooy (The Netherlands)  
E Veys (Belgium)  
A Wiik (Denmark)

**Guidelines for Authors and Reviewers**

Guidance for authors and reviewers can be found at <http://ard.bmj.com/ifora>  
All papers must be submitted via Bench>Press at <http://submit-ard.bmj.com>

**Disclaimer**

*Annals of the Rheumatic Diseases* is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Subscription Information**

See p iv  
ISSN 0003-4967 (print); 1468-2060 (online)


**Copyright**

© 2007 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

• Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/ifora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Score sheet for tenosynovitis in a wrist with RA. See p1216

**Editorial**

1129 What does the clinician need to improve patient care in systemic sclerosis? *M C Vonk, F H J van den Hoogen, P L C M van Riel, G Valentini*

**Reviews**

1132 What effects might anti-TNF $\alpha$  treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF $\alpha$  in cardiovascular pathophysiology *W G Dixon, D P M Symmons*

1137 Vitamin D and autoimmunity: new aetiological and therapeutic considerations *Y Arnson, H Amital, Y Shoenfeld*

**Extended reports**

1143 Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent *J Adriaansen, M Khoury, C J de Cortie, F J Fallaux, P Bigey, D Scherman, D J Gould, Y Chernajovsky, F Apparailly, C Jorgensen, M J B M Vervoordeldonk, P P Tak*

1151 Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis *F Behrens, A Himsel, S Rehart, J Stanczyk, B Beutel, S Y Zimmermann, U Koehl, B Möller, S Gay, J P Kaltwasser, J M Pfeilschifter, H H Radeke*

1157 Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper *M Kloppenburg, T Stamm, I Watt, F Kainberger, T E Cawston, F N Birrell, I F Petersson, T Saxne, T K Kvien, B Slatkowsky-Christensen, M Dougados, L Gossec, F C Breedveld, J S Smolen*

1162 Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab *N Nishimoto, J Hashimoto, N Miyasaka, K Yamamoto, S Kawai, T Takeuchi, N Murata, D van der Heijde, T Kishimoto*

1168 Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) *G S Alarcón, G McGwin, A M Bertoli, B J Fessler, J Calvo-Alén, H M Bastian, L M Vilá, J D Reveille, for the LUMINA Study Group*

1173 Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality *S A Chambers, S C Charman, A Rahman, D A Isenberg*

1178 Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial *M Rother, B J Lavins, W Kneer, K Lehnhardt, E J Seidel, S Mazgareanu*

1184 Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second



[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

Ann Rheum Dis: first published as on 1 September 2007. Downloaded from <http://ard.bmj.com/> on September 25, 2020 by guest. Protected by copyright.

- tumor necrosis factor alpha inhibitor?  
*E Hjarde, M Østergaard, J Pødenphant, U Tarp, L S Andersen, J Bing, E Peen, H M Lindegaard, V S Ringsdal, A Rødgaard, J Skøt, A Hansen, H H Mogensen, J Unkerskov, M L Hetland*
- 1190 Does knee pain in the community behave like a regional pain syndrome? Prospective cohort study of incidence and persistence  
*K T Palmer, I Reading, M Calnan, C Linaker, D Coggon*
- 1195 Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis  
*S Ødegård, A Finset, P Mowinckel, T K Kvien, T Uhlig*
- 1202 Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis  
*A Servettaz, P Guilpain, C Goulvestre, C Chéreau, C Hercend, C Nicco, L Guillevin, B Weill, L Mouthon, F Batteux*
- 1210 Polymorphism of immunoglobulin enhancer element HS1,2A: allele \*2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency  
*D Frezza, V Giambra, B Talusso, M De Santis, S Bosello, S Vettori, G Triolo, G Valentini, G Ferraccioli*
- 1216 Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study  
*E A Haavardsholm, M Østergaard, B J Ejlberg, N P Kvan, T K Kvien*
- 1221 Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan  
*T Matsui, Y Kuga, A Kaneko, J Nishino, Y Eto, N Chiba, M Yasuda, K Saisho, K Shimada, S Tohma*
- 1227 Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)  
*Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, C F Allaart, P J S M Kerstens, B A M Grillet, M H de Jager, K H Han, I Speyer, P A H M van der Lubbe, P E H Seys, F C Breedveld, B A C Dijkmans*
- 1233 Double-blinded infliximab dose escalation in patients with rheumatoid arthritis  
*M U Rahman, I Strusberg, P Geusens, A Berman, D Yocum, D Baker, C Wagner, J Han, R Westhovens*
- 1239 A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow  
*G McKellar, E Morrison, A McEntegart, R Hampson, A Tierney, G Mackle, J Scoular, J A Scott, H A Capell*
- 1244 Body composition and knee cartilage properties in healthy, community-based adults  
*Y Wang, A E Wluka, D R English, A J Teichtahl, G G Giles, R O'Sullivan, F M Cicuttini*
- .....
- ## Concise reports
- 1249 Contribution of anti-cyclic citrullinated peptide antibody and rheumatoid factor to the diagnosis of arthropathy in haemochromatosis  
*E Aigner, I Schmid, C H Österreicher, J Zwerina, G Schett, M Strasser, F Niksic, F Hohla, T Ramsauer, U Dorn, W Patsch, C Datz*
- 1252 Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation  
*M K de Vries, G J Wolbink, S O Stapel, H de Vrieze, J C van Denderen, B A C Dijkmans, L A Aarden, I E van der Horst-Bruinsma*
- 1255 Optic neuritis occurring with anti-tumour necrosis factor  $\alpha$  therapy  
*I Simsek, H Erdem, S Pay, G Sobaci, A Dinc*
- 1259 B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response  
*K P Ng, G Cambridge, M J Leandro, J C W Edwards, M Ehrenstein, D A Isenberg*
- .....
- ## Letters
- 1263 Protective effect of A at position -168 in the type III promoter of the *MHCIIA* gene in systemic lupus erythematosus  
*H Okamoto, H Kaneko, C Terai, N Kamatani*
- 1264 Crico-thyroid perichondritis leading to sore throat in patients with active adult-onset Still's disease  
*D-Y Chen, H H-C Lan, T-Y Hsieh, H-H Chen, J-L Lan*
- 1266 The low-penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis  
*D E Jenne, P M Aries, S Einwächter, A D Akkad, S Wieczorek, P Lamprecht, W L Gross*
- 1267 Serum serotonin levels are not useful in diagnosing fibromyalgia  
*G Jaschko, U Hepp, M Berkhoff, M Schmet, B A Michel, S Gay, H Sprott*
- .....
- 1268 Forthcoming events